Skip to content

Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients

Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients: Preliminary Reports.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05163613
Enrollment
120
Registered
2021-12-20
Start date
2020-01-01
Completion date
2025-01-01
Last updated
2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, COVID-19 Pneumonia, COVID-19 Respiratory Infection

Keywords

COVID-19, magnetostimulation, interleukin, treatment

Brief summary

The purpose of this study was to evaluate the efficacy of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, i.e., including magnetostimulation in the standard treatment. The authors evaluated among other things, the immunocorrective therapeutic effect of magnetostimulation, improving the defensive functions of the immune system and thus supporting the immune function by, among other things, suppressing the cytokine storm. After application of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, the authors expected: a decrease in the level of proinflammatory factors (IL - 6), restoration of homeostasis in the body with regards to the range of parameters evaluated in laboratory tests (WBC, MONO, PLT, CRP, d-dimers) and normalization of the following parameters: arterial blood pressure, the number of breaths/min, saturation, temperature.

Detailed description

Study aim: The purpose of this study was to evaluate the efficacy of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, i.e., including magnetostimulation in the standard treatment. Material and methods: The study was conducted on patients aged 39 to 80 years, of both sexes affected by COVID-19. The study subjects were recruited at the Covid Unit of the Military Medical Academy University Teaching Hospital - Central Veterans' Hospital in Lodz. The study group (13 patients) included patients hospitalized due to PCR (polymerase chain reaction)-confirmed SARS (severe acute respiratory syndrome) -Cov-2 infection, who were treated with magnetostimulation in addition to a standard therapy. The control group (10 patients) included patients receiving a comprehensive treatment without magnetostimulation. The patients hospitalized due to PCR-confirmed SARS - Cov - 2 infection were qualified for the study. Patients with absolute contraindications to magnetic field application and patients with limited verbal - logical contact were excluded from the study. In the study groups, the patients were subjected to magnetic field - magnetostimulation with the use of apparatus Viofor JPS System (mata). 14 treatments were performed, 7 times a week. Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak. In laboratory tests, the following levels were assessed in the patients: interleukin 6 (IL -6), leukocytes (WBC), monocytes (MONO), platelets (PLT), CRP and d-dimers. The patients' blood was taken twice: on admission to the department and after a series of treatments with magnetostimulation. Approximately 6 ml of blood was collected at one time (3 tubes). Medical records of the patients and scientific reports collected from the University Library and medical databases, e.g. PubMed, were analyzed and discussed.

Interventions

OTHERmagnetostimulation

Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.

OTHERstandard therapy

Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.

Sponsors

Medical University of Lodz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
39 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

\- patients hospitalized due to PCR-confirmed SARS - Cov - 2 infection

Exclusion criteria

* patients with absolute contraindications to magnetic field application * patients with limited verbal - logical contact were excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
the number of breaths/min14 daysnormalization of the number of breaths/min
saturation14 daysnormalization of saturation
temperature14 daysnormalization of temperature
the level of proinflammatory factors (IL - 6)14 daysdecrease in the level of proinflammatory factors (IL - 6)
the level of leukocytes (WBC)14 daysrestoration of homeostasis in the body with regards to the range of WBC
the level of monocytes (MONO)14 daysrestoration of homeostasis in the body with regards to the range of MONO
the level of platelets (PLT),14 daysrestoration of homeostasis in the body with regards to the range of PLT
the level of CRP (c reactive protein)14 daysrestoration of homeostasis in the body with regards to the range of CRP
the level of d-dimers.14 daysrestoration of homeostasis in the body with regards to the range of d-dimers
arterial blood pressure,14 daysnormalization of the arterial blood pressure,

Countries

Poland

Contacts

Primary ContactAgnieszka Jankowska, doctor
agnieszka.jankowska@umed.lodz.pl532519534
Backup ContactMarta Woldańska-Okońska, profesor
marta.woldanska-okonska@umed.lodz.pl601377610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026